Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;22(4):457-465.
doi: 10.1007/s40257-021-00595-7. Epub 2021 Mar 23.

Rosacea: New Concepts in Classification and Treatment

Affiliations
Review

Rosacea: New Concepts in Classification and Treatment

Esther J van Zuuren et al. Am J Clin Dermatol. 2021 Jul.

Abstract

Rosacea is a chronic inflammatory dermatosis mainly affecting the cheeks, nose, chin, and forehead. Rosacea is characterized by recurrent episodes of flushing or transient erythema, persistent erythema, phymatous changes, papules, pustules, and telangiectasia. The eyes may also be involved. Due to rosacea affecting the face, it has a profound negative impact on quality of life, self-esteem, and well-being. In addition to general skin care, there are several approved treatment options available for addressing these features, both topical and systemic. For some features, intense pulse light, laser, and surgery are of value. Recent advances in fundamental scientific research have underscored the roles of the innate and adaptive immune systems as well as neurovascular dysregulation underlying the spectrum of clinical features of rosacea. Endogenous and exogenous stimuli may initiate and aggravate several pathways in patients with rosacea. This review covers the new phenotype-based diagnosis and classification system reflecting pathophysiology, and new and emerging treatment options and approaches. We address new topical and systemic formulations, as well as recent evidence on treatment combinations. In addition, ongoing studies investigating novel therapeutic interventions will be summarized.

PubMed Disclaimer

Conflict of interest statement

EJ v Z, MMD vd L, BWMA, SV and ZF: none. JT: advisor, consultant, investigator and/or speaker and has received honoraria and grants from Almirall, Alfasigma, Bausch Health, Boots-Walgreens, Botanix, Cipher, Galderma, L’Oreal, Promius, Sun.

References

    1. van Zuuren EJ. Rosacea. N Engl J Med. 2017;377:1754–1764. doi: 10.1056/NEJMcp1506630. - DOI - PubMed
    1. Tan J, Almeida LM, Bewley A, et al. Updating the diagnosis, classification and assessment of rosacea: recommendations from the global ROSacea Consensus (ROSCO) 2019 panel. Br J Dermatol. 2017;176:431–438. doi: 10.1111/bjd.15122. - DOI - PubMed
    1. Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2018;78:148–155. doi: 10.1016/j.jaad.2017.08.037. - DOI - PubMed
    1. Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea Consensus 2019 panel. Br J Dermatol. 2020;182:1269–1276. doi: 10.1111/bjd.18420. - DOI - PMC - PubMed
    1. van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. Br J Dermatol. 2019;181:65–79. doi: 10.1111/bjd.17590. - DOI - PMC - PubMed

Substances